Rituximab utilization for approved and off‐label nononcology indications and patients’ experiences with the Patient Alert Card

Rituximab utilization for approved and off‐label nononcology indications and patients’ experiences with the Patient Alert Card

Abstract This study used retrospective chart review and survey data to evaluate: (1) off‐label use of rituximab (MabThera®/Rituxan®) in autoimmune conditions and (2) patients’ receipt and knowledge of the Patient Alert Card (PAC), a risk minimization measure for progressive multifocal leukoencephalo...

Full description

Bibliographic Details
Main Authors: Khaled Sarsour, Senam Beckley‐Kartey, Simone Melega, Adefowope Odueyungbo, Petra Kirchner, Natasha Khalife, Joanne Bangs
Format: Article
Language:English
Published: Wiley 2020-02-01
Series:Pharmacology Research & Perspectives
Subjects:
anti‐CD20
infection
off‐label
Patient Alert Card
progressive multifocal leukoencephalopathy
rituximab
Online Access:https://doi.org/10.1002/prp2.555

Internet

https://doi.org/10.1002/prp2.555

Similar Items